Abstract
Objective: Tamoxifen (TAM) is a nonstreroidal antiestrogenic pharmaceutical agent extensively employed in the therapeutic management of breast cancer. Alterations in the expression patterns of diverse ion channels have been implicated in the pathophysiology of breast cancer. The principal objective of this investigation was to elucidate the impact of TAM on the expression of the hERG1 potassium channel in the MCF-7 cell line. Methods: Cytotoxicity induced by TAM across various concentrations was assessed through the utilization of the MTT method. The patch clamp method was employed for electrophysiological analyses. The gene expression of the hERG1 potassium channel was quantified utilizing RT-qPCR. Results: The electrophysiological findings revealed reduction in potassium channel currents, reaching maximal inhibition at a TAM concentration of 5 μM. Concurrently, hERG1 potassium channel gene expression exhibited a decrease at the 5 μM TAM concentration. Despite statistical analysis, no statistically significant values were identified in both potassium channel currents and gene expression analyses when compared to the control group. Our results demonstrate that the blocking effect of TAM on potassium channel currents in the MCF-7 cell line was not determined. Conclusions: Further investigations are warranted to elucidate comprehensively the role of TAM in modulating hERG1 in breast cancer.
Similar content being viewed by others
DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
Ponce-Balbuena, D., López-Izquierdo, A., Ferrer, T., Rodríguez-Menchaca, A.A., AréchigaFigueroa, I.A., and Sánchez-Chapula, J.A. J. Pharmacol. Exp. Ther., 2009, vol. 331, pp. 563–73. https://doi.org/10.1124/jpet.109.156075
Fermini, B., Top. Med. Chem., 2008, vol. 3, pp. 1–25.
Hassan, F., Mohammed, G., El-Hiti, G.A., Alshanon, A., and Yousif, E., J. Unexplored Med. Data, 2018, vol. 3, pp. 1–9. https://doi.org/10.20517/2572-8180.2017.25
Mazzone, M., Menga, A., and Castegna, A., FEBS J., 2018, vol. 285, pp. 700–716. https://doi.org/10.1111/febs.14295
Prevarskaya, N., Skryma, R., and Shuba, Y., Cell Press, 2010, pp. 107–121. https://doi.org/10.1016/j.molmed.2010.01.005
Schönherr, R., J. Membrane Biol., 2005, vol. 205, pp.175–184. https://doi.org/10.1007/s00232-005-0782-3
Kunzelmann, K., J. Membrane Biol., 2005, vol. 205, pp. 159–173. https://doi.org/10.1007/s00232-005-0781-4
Raschi, E., Vasina, V., Poluzzi, E., and De Ponti, F., Pharmacol. Res., 2008, vol. 57, pp. 181–195. https://doi.org/10.1016/j.phrs.2008.01.009
Wang, H., Zhang, Y., Cao, L., Han, H., Wang, J., Yang, B, Nattel, S., and Wang, Z., Cancer Res., 2002, vol. 62, pp. 4843–4848.
Asher, V., Sowter, H., Shaw, R., Bali, A., and Khan, R., World J. Surg. Oncol., 2010, vol. 8, p. 113. https://doi.org/10.1186/1477-7819-8-113
Felipe, A., Vicente, R., Villalonga, N., Roura-Ferrer, M., Martı’nez-Ma’rmol, R., Sole’ L, Ferreres, J.C., and Condom, E., Cancer Detect. Prev., 2006, vol. 30, pp. 375–385. https://doi.org/10.1016/j.cdp.2006.06.002
Wonderlin, W.F. and Strobl, J.S., J. Membr. Biol., 1996, vol. 154, pp. 91–107. https://doi.org/10.1007/s002329900135
Allen, M.C., Newland, C., Valverde, M.A., and Hardy, S.P., Eur. J. Pharmacol., 1998, vol. 354, pp. 261–269. https://doi.org/10.1016/s0014-2999(98)00454-3
Thomas, D., Gut, B., Karsai, S., Wimmer, A.B., Wu, K., Wendt-Nordahl, G., Zhang, W., Kathöfer, S., Schoels, W., Katus, H.A., Kiehn, J., and Karle, C.A., Naunyn Schmiedebergs Arch. Pharmacol., 2003, vol. 368, pp. 41–48. https://doi.org/10.1007/s00210-003-0766-8
Lee, H.J., Choi, J.S., Choi, B.H., and Hahn, S.J., Naunyn Schmiedebergs Arch., Pharmacol., 2017, vol. 390, pp. 633–642. https://doi.org/10.1007/s00210-017-1364-5
Wang, Z., Eur. J. Physiol., 2004, vol. 448, pp. 274–286. https://doi.org/10.1007/s00424-004-1258-5
Pardo, L.A., Physiology, 2004, vol. 19, pp. 285–292. https://doi.org/10.1152/physiol.00011
Chae, Y.J., Lee, K.J., Lee, H.J., Sung, K.W., Choi, J.S., Lee, E.H., and Hahn, S.J., Eur. J. Pharmacol., 2015, vol.752, pp. 1–7. https://doi.org/10.1016/j.ejphar.2015.01.048
Pardo, L.A., del Camino, D., Sanchez, A., Alves, F., Bruggemann, A., Beckh, S., and Stuhmer, W., EMBO J., 1999, vol. 18, pp. 5540–5547. https://doi.org/10.1093/emboj/18.20.5540
Firth, A.L., Remillard, C.V., Platoshyn, O., Fantozzi, I., Eun, A., Ko, E.A., and Yuan, J.X.Y., Pulm. Circlulat., 2011, vol. 1, pp. 48–71. https://doi.org/10.4103/2045-8932.78103
Smith, G.A.M., Tsui, H.W., Newell, E.W., Jiang, X., Zhu, X.P., Tsui, F.W.L., and Schlichter, L.C., J. Biol. Chem., 2002, vol. 277, pp. 18528–18534. https://doi.org/10.1074/jbc.M200592200
Ohkubo, T. and Yamazaki, J., Int. J. Oncol., 2012, vol. 41 pp. 267–275. https://doi.org/10.3892/ijo.2012.1422
Ouadid-Ahidouch, H., Chaussade, F., Roudbaraki, M., Slomianny, C., Dewailly, E., Delcourt, P., and Prevarskaya, N., Biochem. Biophys. Res. Commun., 2000, vol. 278, pp. 272–277. https://doi.org/10.1006/bbrc.2000.3790
Lastraioli, E., Lottini, T., Iorio, J., Freschi, G., Fazi, M., and Duranti, C., Oncotarget., 2016, vol.13, pp. 59535–59547.
Crociani, O., Lastraioli, E., Boni, L., Pillozzi, S., Romoli, M.R., and D’Amico, M., Clin. Cancer Res., 2014, vol. 20, pp. 1502–1512. https://doi.org/10.1158/1078-0432.CCR-13-2633
Muratori, L., Petroni, G., Antonuzzo, L., Boni, L., Iorio, J., and Lastraioli, E., Oncol. Targets Ther., 2016, vol. 14, pp. 6325–6332. https://doi.org/10.2147/OTT.S114090
Iorio, J., Meattini, I., Bianchi, S., Bernini, M., Maragna, V., Dominici, L., Casella, D., Vezzosi, V., Orzalesi, L., Nori, J., Livi, L., Arcangeli, A., and Lastraioli, E., Cancer Cell Int., 2018, vol. 18, p. 93. https://doi.org/10.1186/s12935-018-0592-1
Feng, J., Yu, J., Pan, X., Li, Z., Chen, Z., Zhang, W., Wang, B., Yang, L., Xu, H., Zhang, G., and Xu, Z., Oncotarget., 2014, vol. 5, pp. 5832–5844. https://doi.org/10.18632/oncotarget.2200
Shao, X.D., Wu, K.C., Guo, X.Z., Xie, M.J., Zhang, J., and Fan, D.M., Cancer Biol. Ther., 2008, vol. 7, pp. 45–50. https://doi.org/10.4161/cbt.7.1.5126
Abdullah, Y., Cureus, 2023, vol. 15, p. e47501. https://doi.org/10.7759/cureus.47501
Tsang, S.Y., Yao, X., Wong, C.M., Chan, F.L., Chen, Z.Y., and Huang, Y., Eur. J. Pharmacol., 2004, vol. 483, pp. 155–162. https://doi.org/10.1016/j.ejphar.2003.10.031
Vajrabhaya, L. and Korsuwannawong, S., JAST, 2018, pp. 9–15. https://doi.org/10.1186/s40543-018-0146-0
Helliwell, R.M., Potassium Channels: Method. Protocol., 2009, pp. 279–295.
Zhang, X., Yu, D., Geng, H., Li, F., Lv, L., Zhao, L., Yan, C., and Li, B., Oncol. Lett., 2018, vol. 16, pp. 3812–3820.
Funding
The authors would like to thank to Mersin University Scientific Research Project Unit for financial support (no. BAP-SBEBK(PE)2011-3DR).
Author information
Authors and Affiliations
Contributions
The authors PE, FS, SY, UC, and NSY designed the experiments. The authors PE, FS, DY, and NSY carried out their biological study. The authors PE, SY, FS, UC, NSY, and SE participated in data processing and contributed to manuscript preparation.
All authors participated in the discussions.
Corresponding author
Ethics declarations
This article does not contain any studies involving patients or animals as test objects.
Informed consent was not required for this article. No conflict of interest was declared by the authors
Additional information
Publisher's Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Eroglu, P., Sogut, F., Yetkin, D. et al. Investigation of the Effect of Tamoxifen on hERG1 Potassium Channel Gene Expression in MCF-7 Cell Line. Russ J Bioorg Chem 50, 392–400 (2024). https://doi.org/10.1134/S106816202402016X
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S106816202402016X